Adamas Pharmaceuticals Inc (ADMS) : Mosaic Family Wealth added new position in Adamas Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 123,314 shares of Adamas Pharmaceuticals Inc which is valued at $1,664,739 , the company said in a statement filed on Aug 15, 2016 with the SEC.Adamas Pharmaceuticals Inc makes up approximately 0.75% of Mosaic Family Wealth’s portfolio.
Other Hedge Funds, Including , Zacks Investment Management reduced its stake in ADMS by selling 360 shares or 0.79% in the most recent quarter. The Hedge Fund company now holds 45,273 shares of ADMS which is valued at $611,186. Adamas Pharmaceuticals Inc makes up approx 0.02% of Zacks Investment Management’s portfolio.New York State Common Retirement Fund boosted its stake in ADMS in the latest quarter, The investment management firm added 8,600 additional shares and now holds a total of 18,100 shares of Adamas Pharmaceuticals Inc which is valued at $244,350.Dimensional Fund Advisors Lp boosted its stake in ADMS in the latest quarter, The investment management firm added 1,300 additional shares and now holds a total of 60,550 shares of Adamas Pharmaceuticals Inc which is valued at $802,288.Ubs Asset Management Americas Inc reduced its stake in ADMS by selling 12,171 shares or 41.57% in the most recent quarter. The Hedge Fund company now holds 17,110 shares of ADMS which is valued at $230,130. Strs Ohio sold out all of its stake in ADMS during the most recent quarter. The investment firm sold 38,800 shares of ADMS which is valued $566,480.
Adamas Pharmaceuticals Inc opened for trading at $13.74 and hit $15.12 on the upside on Thursday, eventually ending the session at $15.07, with a gain of 10.24% or 1.4 points. The heightened volatility saw the trading volume jump to 4,41,260 shares. Company has a market cap of $330 M.
Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Noble Financial Initiated Adamas Pharmaceuticals Inc on Jun 17, 2016 to “Buy”, Price Target of the shares are set at $25.Mizuho Upgraded Adamas Pharmaceuticals Inc on Jun 16, 2016 to ” Buy”, Price Target of the shares are set at $22.
Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.